Envue Medical, Inc. 8-K Filing
Ticker: FEED · Form: 8-K · Filed: Dec 30, 2025 · CIK: 1326706
| Field | Detail |
|---|---|
| Company | Envue Medical, Inc. (FEED) |
| Form Type | 8-K |
| Filed Date | Dec 30, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Envue Medical, Inc. (ticker: FEED) to the SEC on Dec 30, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share NAOV Nasdaq Capital Marke).
How long is this filing?
Envue Medical, Inc.'s 8-K filing is 2 pages with approximately 605 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 605 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-12-30 06:09:39
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NAOV Nasdaq Capital Marke
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex10-1.htm (EX-10.1) — 256KB
- 0001493152-25-029482.txt ( ) — 504KB
- feed-20251224.xsd (EX-101.SCH) — 3KB
- feed-20251224_lab.xml (EX-101.LAB) — 33KB
- feed-20251224_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 24, 2025, the Board of Directors of ENvue Medical, Inc. (the " Company ") approved the amendment and restatement of the 2024 Long Term Incentive Plan (as amended and restated, the " Amended and Restated Plan "). The Amended and Restated Plan amends the definition of Awards (as defined in the Amended and Restated Plan), for Israeli law purposes, to include restricted stock units, or such other Awards as may be granted under Section 102 (as defined in the Amended and Restated Plan) to comply with certain Israeli tax laws and requirements. The Amended and Restated Plan further reflects certain non-material updates, including but not limited to (i) certain updates made in connection with the Company's name change from "NanoVibronix, Inc." to "ENvue Medical, Inc." and (ii) updates as related to the First Amendment to the 2024 Long Term Incentive Plan, as approved by the stockholders of the Company on December 4, 2025. The description of the Amended and Restated Plan is qualified in its entirety by reference to the full text of the Amended and Restated Plan, filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Financial Statements
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amended and Restated 2024 Long Term Incentive Plan of ENvue Medical, Inc., dated as of December 24, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NanoVibronix, Inc . Date: December 30, 2025 By: /s/ Doron Besser, M.D. Name: Doron Besser, M.D. Title: Chief Executive Officer